7,870$
-0,88%
Echtzeit-Aktienkurs Niagen Bioscience Inc.
Bid:
Ask:
Echtzeit-Chart der Niagen Bioscience Inc. Aktie
Börsenkurse Niagen Bioscience Inc.
| gettex | - | - | - | - | 9,850€ | 3,41% |
| USA | - | - | - | - | 7,870$ | -0,88% |
| Echtzeit Euro | - | - | - | - | 9,875€ | 5,05% |
| Börse Stuttgart | - | - | - | - | 9,700€ | 2,11% |
| Tradegate | - | - | - | - | 9,850€ | 1,03% |
| Börse Frankfurt | - | - | - | - | 9,875€ | 5,05% |
| Echtzeit USD | - | - | - | - | 11,475$ | 3,61% |
| Nasdaq | - | - | - | - | 11,505$ | 3,84% |
| Lang & Schwarz | - | - | - | - | 9,875€ | 3,13% |
Fundamentaldaten der Niagen Bioscience Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 99,60 Mio. | 8,86 Mio. | 8,55 Mio. | 0,11 | - | 72,20 | 6,11 |
| 2023 [USD] | 83,57 Mio. | -4,94 Mio. | -4,94 Mio. | -0,07 | - | - | 7,06 |
| 2022 [USD] | 72,05 Mio. | -16,54 Mio. | -16,54 Mio. | -0,24 | - | - | 8,14 |
| 2021 [USD] | 67,45 Mio. | -27,13 Mio. | -27,13 Mio. | -0,40 | - | - | 7,95 |
| 2020 [USD] | 59,26 Mio. | -19,93 Mio. | -19,93 Mio. | -0,33 | - | - | 8,22 |
| 2019 [USD] | 46,29 Mio. | -32,15 Mio. | -32,15 Mio. | -0,56 | - | - | 10,13 |
| 2018 [USD] | 31,56 Mio. | -33,32 Mio. | -33,32 Mio. | -0,61 | - | - | 13,74 |
| 2017 [USD] | 21,20 Mio. | -16,53 Mio. | -16,84 Mio. | -0,38 | - | - | 20,30 |
| 2016 [USD] | 26,81 Mio. | -2,93 Mio. | -2,93 Mio. | -0,08 | - | - | 11,02 |
| 2015 [USD] | 22,01 Mio. | -2,77 Mio. | -2,77 Mio. | -0,08 | - | - | 12,87 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Niagen Bioscience Inc. Aktie
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr